Ipsen is acquiring global rights to a Sutro Biopharma antibody drug conjugate for a target that is not yet hit by any FDA-approved drugs. Merck is among the companies pursuing this target, but Sutro claims its ADC could be first and best in this class.
The post Ipsen Joins the ADC Chase, Licensing Phase 1-Ready Asset for Novel Cancer Target appeared first on MedCity News.
Related Articles
Links
Hatch Waxman turns 40. FDA: Integrating RCT into routine clinical practice. Cost...
What Are the Challenges in Building a Consumer-Focused Diagnostic Testing Startup?
During a panel discussion at the MedCity News INVEST Digital Health Conference,...
BREAKING: FG Moves To Decriminalise Suicide Attempts
FG has moved to decriminalise suicide attempts. NewsOnline Nigeria reports that...
New XEC Covid variant: What are the symptoms and is it spreading in the UK?
The Covid-19 pandemic is constantly changing, with new variants appearing occasionally. Lately,...
Leave a comment